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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the efficacy of non-speech oral motor treatment (NSOMT) for treating developmental speech sound disorders.
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B A C K G R O U N D
Description of the condition
Developmental speech sound disorder is a generic term that refers
to clinically significant problems in producing the speech sounds
of the language in children. This can be a secondary impact of
a structural deficit of the articulators (for example, cleft palate),
a sensory or motor disorder (for example, hearing impairment)
or a neuromuscular disorder (for example, dysarthria, apraxia of
speech). Alternatively, it may be a primary disorder where the
cause is unknown (Ruscello 2008a; Flipsen 2009; Shriberg 2010).
Speech problems can have damaging effect on many aspects of
life. For example, they could hamper daily communication, caus-
ing difficulties in socialisation. It has been reported that about
50% to 70% of children with speech sound disorder show general
difficulty with this through to secondary education (see Williams
2010). This could impair self-esteem, which in turn could affect
quality of life.
It has been estimated that around 7.5% of children between the
age of three and 11 years show clinically significant speech sound
disorders (Shriberg 1994). Children with developmental speech
sound disorders account for a large proportion of speech and lan-
guage therapists’ (SLTs) caseloads, nearly half of a typical caseload
for the clinicians in the United Kingdom and Australia (see Joffe
2008). In the United States, it has been estimated that about 80%
of children with speech sound disorders require treatment services
and about 92% of school-based speech-language pathologists pro-
vide treatment services to children with speech sound disorders
(see Ruscello 2008a).
Description of the intervention
Phonetic and phonemic treatments
Different treatment approaches for managing speech sound disor-
ders have been developed and they can be categorised broadly into
phonetic (or sensory motor-based) treatments, phonemic (or con-
ceptual-based) treatments, and hybrid treatments that incorpo-
rate both phonetic and phonemic components (Ruscello 2008b).
Phonetic treatments focus on improving the accuracy of articu-
latory movements for the speech sounds through different lev-
els of practice, from an isolated sound level to attain correct tar-
get sound production to nonsense syllables, words, phrases, and
finally conversational speech (Ruscello 2008a; Ruscello 2008b).
For phonemic treatments, the aim is to restructure or develop
the children’s phonological knowledge through different types of
contrastive practice (for example, minimal pairs) or metalinguistic
awareness tasks (for example,metaphon), or both (Ruscello 2008a;
Ruscello 2008b). Hybrid treatments are a combination of pho-
netic and phonemic treatments in which both phonetic practice
and phonemic contrast are employed in the treatment (Ruscello
2008a).
The clinical decision of treatment approach is basedmainly on the
cause of the speech disorder. For example, phonetic approaches,
which focus on developing the client’s motor skills, are usually
applied to those who have knowledge of phonological rules of the
language but are unable to produce certain speech sounds correctly.
Speech therapy using phonetic, phonemic, or a combination of
these approaches is regarded as standard speech intervention.
Non-speech oral motor exercises
One alternate treatment approach for managing developmental
speech sound disorder is non-speech oral motor treatments or
exercises (NSOMTs). An operational definition of NSOMTs is
provided by the American Speech-Language-HearingAssociation’s
(ASHA) National Center for Evidence-Based Practice in Com-
munication Disorders. They are “non-speech activities that in-
volve sensory stimulation to or actions of the lips, jaw, tongue,
soft palate, larynx, and respiratory muscles that are intended to
influence the physiological underpinnings of the oropharyngeal
mechanism to improve its function. They may include activities
described as active muscle exercise, muscle stretching, passive ex-
ercise, or sensory stimulation” (McCauley 2009, p 344).
NSOMTs are different from the phonetic and phonemic treat-
ments because they do not involve practice of speech sound ar-
ticulation and auditory discrimination of the error sound and the
target sound. Instead, they target non-speech motor movements
and oral postures with the aim of developing motor skills for cor-
rect speech sound production (Ruscello 2008a). For example, by
doing exercises with the lips in non-speech activities, such as blow-
ing horns, straws, and bubbles, the motor skills developed could
be transitioned to the production of bilabial speech sounds (for
example, /p/ and /b/) (Rosenfeld-Johnson 2001). See the paper by
Ruscello 2008b for details of the different types of NSOMTs.
NSOMTs are used in a variety of ways and for different client
groups. A recent survey conducted in the United States revealed
that most clinicians, 68% of 537 respondents, use NSOMTs as
a ’warm-up’ followed by speech intervention (Lof 2008). About
25% used NSOMTs in conjunction with speech intervention and
7% of the clinicians used NSOMTs exclusively to target speech
productions (Lof 2008). The survey also showed that the clin-
icians often use NSOMTs with children presenting with motor
speech disorders, structural anomalies (for example, cleft palate),
and Down syndrome (Lof 2008). They also use NSOMTs, but
less frequently, with children who are identified as late talkers,
and those with phonological disorders, hearing impairment, and
speech sound disorders with unknown origin (Lof 2008). A survey
conducted in Canada showed slightly different findings. The clin-
icians there are most likely to use NSOMTs with children exhibit-
ing phonological disorders, apraxia of speech, dysarthria, Down
syndrome, and cerebral palsy (Hodge 2005).
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How the intervention might work
The use of NSOMTs for treating speech sound disorders in chil-
dren is motivated by several assumptions (Bunton 2008; Ruscello
2008b; Clark 2010). First, it is assumed that a common set of
control principles, such as force and timing, are used for control-
ling the same structure for conducting different motor activities
(Bunton 2008; Ruscello 2008b). Hence, for example, the move-
ment characteristics and task demands for the production of bil-
abial speech sounds and those for blowing bubbles or kissing are
presumably similar.
Second, the principles of motor learning suggest that breaking
down the complex movements in speech production into subcom-
ponents could facilitate learning by allowing the motor system
to plan simpler movement patterns and gradually develop skilled
control ofmore complexmovement patterns (Bunton 2008; Clark
2010). For example, practising tongue tip-to-alveolar ridge move-
ment gestures for helping the production of alveolar stops (for
example, /t/ and /d/) (Lof 2009).
Third, it is assumed that speech production and non-speech ac-
tivities share common neural anatomical representation in the hu-
man nervous system (Chapman Bahr 2001; Bunton 2008). On
the basis of these assumptions, it is believed that the training ef-
fect from the practice of non-speech oral motor exercises could be
transferred to speech production (Powell 2008).
In theory, NSOMTs are most likely to benefit children who have
speech sound disorders due to sensorimotor impairments (Clark
2010), which means that causation may be an important determi-
nant in the selection and use of NSOMTs.
Why it is important to do this review
NSOMTs are used extensively by clinicians when treating devel-
opmental speech sound disorders. Recent surveys reported that
between 71.5% and 85% of speech and language therapists in the
United Kingdom and speech-language pathologists in the United
States and Canada use NSOMTs (Hodge 2005; Joffe 2008; Lof
2008). There had not been a systematic review on this issue until
the recent work by McCauley and colleagues (McCauley 2009);
however this systematic reviewwas not conducted according to the
standards set by The Cochrane Collaboration. There are a num-
ber of limitations as the types of studies were not limited to ran-
domised clinical trials (RCTs) and quasi-RCTs; only studies pub-
lished in English were included for review; and the literature search
was limited to databases that encompass peer-reviewed journals.
There are Cochrane systematic reviews on the efficacy of speech
intervention for speech problems related to childhood apraxia of
speech (Morgan 2008a), dysarthria associated with acquired brain
injury (Morgan 2008b), and primary speech and language delay or
disorder (Law 2003). These reviews planned to compareNSOMTs
to standard speech intervention and to evaluate the treatment effi-
cacy on three levels of outcomes. However, whether factors such as
frequency of therapy sessions and the presence or absence of intel-
lectual disability could affect the treatment efficacy of NSOMTs
is uncertain. Although there could be some overlap with these
systematic reviews, this review will cover a broader spectrum of
developmental conditions and subsequently provide a more in-
depth evaluation of the treatment efficacy of NSOMTs.
Given the high incidence of speech sound disorders and the
abundance of commercial products and training workshops for
NSOMTs (Kamhi 2008), there is a pressing need to examine the
evidence regarding the efficacy of NSOMTs so that clinicians can
make informed decisions in their treatment planning. Moreover,
clients and their families also need to be made aware of the evi-
dence relating to efficacy, or lack thereof, for treatments that in-
volve NSOMTs.
O B J E C T I V E S
To assess the efficacy of non-speech oral motor treatment
(NSOMT) for treating developmental speech sound disorders.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised and quasi-randomised controlled trials
(for example, studies in which participants were allocated to treat-
ments by, for example, alternate allocation or allocation by date
of birth). Trials using cross-over design will be excluded from the
review as this is considered inappropriate for studying speech in-
tervention.
Types of participants
Individuals aged three to 16 years with developmental speech
sound disorders, as judged by speech and language therapist(s).
Individuals with intellectual disability (for example, Down syn-
drome) and physical disability will not be excluded.
Types of interventions
Non-speech oralmotor treatment versus treatmentwith placeboor
control.Wewill also includeNSMOTS as an adjunctive treatment
if speech intervention with NSOMTs is compared with speech
intervention alone. There will be no restriction on the frequency,
intensity, and duration of intervention.
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Types of outcome measures
Primary outcomes
1. Correct articulation of speech sounds targeted in the
treatment, as measured by standardised tests (for example,
Edinburgh Articulation Test (Anthony 1971)) or non-
standardised articulation tests (for example, per cent correct
speech sounds produced based on perceptual evaluation of
articulation).
2. Speech intelligibility measured using a perceptual rating
scale or percentage of words correctly transcribed by the
investigator.
3. Speech physiology, as measured by instrumental techniques
such as acoustic analysis (for example, the measure of format
frequencies for assessing vowel productions), kinematic analysis,
and articulatory placement.
4. Adverse effect of an increase in articulation errors after
treatment, which could be measured by the same standardised
and non-standardised tests listed above. These articulation tests
should be conducted by a speech and language therapist.
We will include the first two primary outcomes, correct articula-
tion of speech sounds targeted in the treatment and speech intel-
ligibility, and adverse effects in the ’Summary of findings’ tables.
Secondary outcomes
1. Listener acceptability, speech naturalness or bizarreness (for
example, judged by naive listener(s) using perceptual rating).
2. Self-perception of change in articulation or speech
intelligibility (for example, using a rating scale).
Time points for measuring the outcomes
• Immediately (within one month) after the end of the
intervention.
• One to 12 months after the end of the intervention.
• One to two years after the end of the intervention.
Search methods for identification of studies
Electronic searches
We will search the following databases to identify relevant trials:
Cochrane Central Register of ControlledTrials (CENTRAL) (The
Cochrane Library), MEDLINE (or PubMed), EMBASE, ERIC,
PsycINFO, CINAHL, ISI Web of Knowledge, LILACS, Aca-
demic Search Complete, The National Research Register Archive,
UKCRN, ClinicalTrials.gov, metaRegister of Controlled Trials,
WHO International Clinical Trials Registry Platform (ICTRP),
and ProQuest Dissertations and Theses.
We will use the following search terms to search MEDLINE. We
will modify terms and filters as appropriate for other databases.
No language or date restriction will be applied to the searches.We
will seek translation when necessary.
1. exp Speech Disorders/
2. dysarthri$.tw.
3. (mute or mutism).tw.
4. ((speech or articulat$ or phonetic$ or phonological) adj5
(disorder$ or delay$ or impair$ or problem$)).tw.
5. or/1-4
6. oral motor.tw.
7. oromotor.tw.
8. oro-motor.tw.
9. (NSOM$ or OME).tw.
10. Speech Disorders/rh, th [Rehabilitation, Therapy]
11. (non-speech or nonspeech$).tw.
12. Speech Therapy/
13. or/6-12
14. randomized controlled trial.pt.
15. controlled clinical trial.pt.
16. randomi#ed.ab.
17. placebo$.ab.
18. drug therapy.fs.
19. randomly.ab.
20. trial.ab.
21. groups.ab.
22. or/14-21
23. exp animals/ not humans.sh.
24. 22 not 23
25. 5 and 13 and 24
Searching other resources
Wewill check reference lists of relevant journal papers, book chap-
ters, and systematic reviews which are identified by the electronic
searches. We will approach colleagues and researchers by email to
identify other possible published and unpublished studies, such as
technical or research reports, conference papers, and dissertations.
We will use Google to find websites of relevant organisations, and
will search these using appropriate search terms from the strategy
above.
Data collection and analysis
Selection of studies
One review author (AL) will conduct the literature search. We
will manage all references generated from the search strategy us-
ing a reference management programme (EndNote). The two re-
view authors (AL and FG) will independently conduct an initial
screening of titles and abstracts to eliminate any references that
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are apparently irrelevant to the review (for example, single case
studies). In cases where an abstract contains insufficient informa-
tion for judging whether a study meets the inclusion criteria, we
will obtain the full paper. AL and FG will then independently
evaluate each paper against the inclusion criteria. In the event of
disagreement over inclusion of a particular paper, AL and FG will
seek to reach a consensus by assessing the paper together. We will
report the disagreement, including the title(s) and the reason(s)
for different judgements between the two review authors, and the
consensus obtained after discussion.
Data extraction and management
We will develop and pilot a data extraction form and subsequent
versions of the form will include revision dates. AL and FG will
independently extract the following information from each paper:
1. participants - number; age; sex; inclusion and exclusion
criteria; severity level of developmental speech sound disorders;
and other baseline characteristics reported (for example, hearing
ability, intellectual disability, etc);
2. methods - speech assessment(s) and outcome measure(s)
used and assessment results (for example, number and types of
articulation errors).
3. interventions - type of interventions; number of therapy
sessions given, duration of each therapy session, frequency of
therapy and length of intervention; date and location; and
whether compliance was evaluated;
4. intervention integrity - using the categories proposed by
Dane and Schneider (Dane 1998), we will record the presence or
absence of features of fidelity verification and promotion (for
example, training manual developed for training intervention
provider).
Assessment of risk of bias in included studies
AL and FG will independently assess the risk of bias in each
included study in the following six domains according to the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). The assessment will consist of two parts: (1) a succinct de-
scription, which will include verbatim quotes from the paper or
correspondence with the trial author(s) or a comment from the re-
view author about the procedures used to avoid bias, or both; and
(2) an assessment of the risk of bias (by assigning a judgement of
‘low risk’, ‘high risk’, or ‘unclear risk’ of bias). We will not include
studies that are judged as ‘high risk’ for each area of potential risk
of bias in subsequent analyses. The judgement criteria for each
domain are described below.
Sequence generation
We will describe the method used to generate the allocation se-
quence using quotes wherever possible. We will add a comment,
such as ‘probably done’ or ‘probably not done’, to supplement any
ambiguous quote. We will assign each included study to one of
the following categories:
• ‘low risk’, which indicates an adequate method was used for
randomisation (for example, computer generated or table of
random numbers) or quasi-randomisation;
• ‘high risk’, which indicates that an inadequate method of
randomisation was used (for example, case file number, date of
birth, or alternate numbers);
• ‘unclear risk’, which indicates uncertainty about whether an
appropriate method of randomisation was used.
Allocation concealment
We will assign the included studies to one of the following quality
criteria whereby:
• ‘low risk’ indicates adequate concealment of allocation (for
example, pre-numbered or coded identical containers
administered serially to participants);
• ‘high risk’ indicates that the allocation was not adequately
concealed (for example, alternate assignment);
• ‘unclear risk’ indicates uncertainty about whether the
allocation was adequately concealed (for example, the authors
did not describe the allocation methods).
Blinding
Blinding of participants and intervention providers (that is, the
SLTs) is not possible but blinding of outcome assessor(s) and data
analyst(s) from knowledge of which intervention a participant had
received should be ensured. We will describe and evaluate the
measures used to ensure blinding. We will grade this domain as
‘low risk’, ‘high risk’, and ‘unclear risk’. Assessmentwill bemade for
eachmain outcome (for example, outcomemeasured at sixmonths
post-therapy, outcome measured at 12 months post-therapy).
Incomplete outcome data
Incomplete outcome data refer to those that were due to attrition
(dropout) during the study, or exclusions from the analysis.Wewill
extract the number of and reason(s) for attrition or exclusions, and
note whether attrition was analysed appropriately (for example,
intention-to-treat analysis).Wewill grade this domain as ‘low risk’,
‘high risk’, and ‘unclear risk’ according to the criteria stated in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
Selective reporting bias
This is also known as within-study publication bias. It may arise
in several ways (Higgins 2011).
• Only some of the analysed outcomes were included in the
study.
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• Different time points at which the outcome was measured,
or different instruments or assessors employed to measure the
outcome at the same time point.
• Selective reporting of analysis using the same data.
• Selectively reporting the results of subscales of full
measurement scale or a subset of events.
• Some outcomes were reported but with inadequate detail
for the data to be included in a meta-analysis.
We will assign the included studies to one of the following quality
criteria whereby:
• ‘low risk’ indicates that the studies have reported all pre-
specified outcomes;
• ‘high risk’ indicates that any of the above-mentioned
selective reporting is evident in the study; and
• ‘unclear risk’ indicates that it is uncertain whether selective
reporting bias is avoided.
Other sources of bias
Other sources of bias may include baseline imbalance, early stop-
ping, and co-intervention. This domain will be graded as ‘low
risk’, ‘high risk’, and ‘unclear risk’.
Measures of treatment effect
Binary and categorical data
Binary data (for example, articulation improved versus no change)
is likely. We will analyse the data by calculating the risk ratio.
Continuous data
Most data from the expected outcome measures, such as stan-
dardised articulation test results, articulation accuracy based on
perceptual evaluation, judgement of speech intelligibility, and lis-
tener acceptability are likely to be continuous data. We will calcu-
late the mean difference (MD, or the ‘difference in means’) if the
outcome measurements in all studies are made on the same scale.
Otherwise, we will use standardised mean differences (SMD) to
combine studies that measured the same outcome using different
methods.
Unit of analysis issues
Cluster-randomised trials
It is possible that we will include cluster-randomised trials in this
review. In this case, appropriate statistical approaches should be
used; for example, using a two-sample t-test to compare themeans
of the clusters in the intervention group to those in the control
group at cluster level, or a mixed effects linear regression approach
at individual level (Donner 2000). We will contact the trial au-
thor(s) in case it is unclear if appropriate adjustments have been
made (Donner 2000). If individual level data cannot be secured,
we will control the data for the clustering effect using the proce-
dures described in the Cochrane Handbook for Systematic reviews of
Interventions (Higgins 2011). For dichotomous data, we will di-
vide the number of participants and the number experiencing the
event by the design effect, 1 + (M-1) * ICC, whereM is the average
cluster size and ICC is the intra-cluster correlation coefficient. For
continuous data, we will divide the number of participants by the
design effect, with the means and standard deviations remaining
unchanged. We will combine the results with those from individ-
ually randomised trials for meta-analysis using the generic inverse-
variance method in RevMan, if the clinical heterogeneity between
studies is small (Donner 2000; Higgins 2011).
Multi-arm studies
For studies withmore than two intervention groups, that is, multi-
arm studies, we will combine groups to create a single pair-wise
comparison (Higgins 2011). We will combine all relevant exper-
imental intervention groups to form a single group, and we will
combine all relevant control groups and placebo groups to form
a single control group. To avoid any confusion over the nature of
each study, we will mention all intervention groups of a multi-
arm study in the ’Notes’ section of the table ’Charactertistics of
included studies’. We will give detailed descriptions of the inter-
vention groups relevant to the review in the ’Interventions’ section
of the table.
Cross-over trials
Cross-over trials are not appropriate for an intervention that can
have a lasting effect (Higgins 2011). Therefore, this design is not
suitable for studying speech intervention and we will not include
studies that employed this design in this review.
Dealing with missing data
We will assess missing data and dropouts for each included study
and report the reasons, numbers, and characteristics of dropouts.
Whenever possible, wewill contact the trial author(s) for supplying
the missing data and any relevant information. If the missing data
appear to be missing at random (for example, data lost due to
computer problems), wewill conduct analysis on the available data
(Higgins 2011).
However, if the data are not missing at random, we will conduct
the analysis by imputing themissing data with replacement values.
For dichotomous data, we will use a sensitivity analysis based on
consideration of ‘best-case’ and ‘worst-case’ scenarios to assess the
extent to which the results of the review could be altered by the
missing data (Gamble 2005). The ‘best-case’ scenario means that
all participants with missing outcomes in the intervention group
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had good outcomes (for example, improvement in articulation)
and those with missing outcomes in the control group had poor
outcomes (for example, no improvement in articulation); and the
‘worst-case’ scenario is the reverse.
For missing continuous data, we will conduct the analysis by im-
puting the missing data with replacement values (for example, last
observation carried forward, mean of the treatment group) and
treating these as if they were observed (Higgins 2011). We will
address the potential impact of missing data on the findings of the
review in the ’Discussion section.
Assessment of heterogeneity
Variability in the participants, interventions, and outcomes be-
tween the different included studies is known as clinical hetero-
geneity, and variability in the intervention effects being evaluated
in the included studies is known as statistical heterogeneity, or sim-
ply as heterogeneity (Higgins 2011). Clinical heterogeneity will
lead to statistical heterogeneity if the intervention effect is affected
by factors such as patient characteristics (Higgins 2011). We will
assess statistical heterogeneity by using the Chi2 test for hetero-
geneity, through visual inspection of forest plots, and by using the
I2 statistic (Higgins 2002; Higgins 2003). The Chi2 test assesses
whether observed differences in results are compatible with chance
alone (Higgins 2011). However, it has low power if the meta-
analysis includes only a small number of studies, or the studies
included have small sample sizes. In this case, a P-value of 0.10
(rather than the conventional level of 0.05) will be used to de-
termine statistical significance (Higgins 2011). I2 is a statistic for
assessing the impact of inconsistency across studies on the meta-
analysis. We will follow the rough guide to interpretation of the I2
statistic stated in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). However, thresholds for the inter-
pretation of the I2 statistic may be misleading. We will take into
account other issues, such as the magnitude and direction of ef-
fects, and the strength of evidence for heterogeneity (for example,
the P value from the Chi2 test), when determining the importance
of the observed value of the I2 statistic (Higgins 2011).
Assessment of reporting biases
Funnel plots (effect size against error) will be drawn if sufficient
studies are found. An asymmetric funnel plot indicates a relation-
ship between effect size and study size, which suggests the possi-
bility of either publication bias or a systematic difference between
smaller and larger studies. If a relationship is identified, the clinical
diversity of the studies will also be examined (Egger 1997).
Data synthesis
We will carry out meta-analysis using Review Manager 5.1
(RevMan), if there are sufficient data and where the interventions
are similar in terms of the characteristics of the participants, the
types of NSOMTs used, the schedule (for example, frequency and
duration) of the treatment, and outcome measures. We will ap-
ply both a fixed-effect and random-effects model and compare
the results to assess the impact of statistical heterogeneity. We will
present the results from the random-effects model unless contra-
indicated (for example, if there is funnel plot asymmetry). In the
case of serious funnel plot asymmetry, we will present both fixed-
effect and random-effects model analyses, under the assumption
that asymmetry suggests that neither model is appropriate. If the
same outcome is presented as dichotomous data in some studies
and as continuous data in other studies, we will convert odds ra-
tios for the dichotomous data to standardised mean differences
(SMD) if it can be assumed that the underlying continuous mea-
surements follow a normal or logistic distribution. Otherwise, we
will conduct separate analyses.
Mutiple time points
For studies where outcomes were measured at different time
points, we will calculate the combined effect size across the differ-
ent time points (Borenstein 2009).
Subgroup analysis and investigation of heterogeneity
If there are sufficient homogenous studies, we will conduct sub-
group analyses to assess the impact of the cause of speech sound
disorders (for example, structural anomalies, neuromuscular im-
pairment, unknownorigin), intensity of therapy (to be determined
by the frequency of therapy sessions), the presence or absence of
intellectual disability, and the use of NSOMTs as an adjunctive to
speech intervention.
Sensitivity analysis
We will examine the impact of study quality on the robustness
of conclusions by performing sensitivity analyses. Factors that are
considered as important in judging study quality include randomi-
sation, blinding to outcome assessment, and attrition (Juni 2001).
We will include studies that we categorised as low or unclear risk
of bias for these factors in the analysis.
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